NK cell

Phase 1Cell therapy

NNanfang Hospital, Southern Medical University

NK cell is one of 29 small molecule programs targeting Acute Myeloid Leukemia (AML). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid Leukemia (AML)Recruiting

Acute Myeloid Leukemia (AML)Phase 1

Recruiting

Competition

Competitive Landscape

33 competitors in Acute Myeloid Leukemia (AML)

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

7 2

Cytosar

Teva

Phase 3

4 3

Xospata

Astellas

Phase 3

3 4

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

9 5

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

3 6

Komzifti

KKura Oncology, Inc.

Phase 3

1 7

Granulocyte Colony-Stimulating Factor

Sanofi

Phase 3

1 8

Lisaftoclax

Ascentage Pharma Group Inc.

Phase 3

2 9

Mitoxantrone Hydrochloride Liposome

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

1 10

AG-120

Institut de Recherches Internationales Servier

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Acute Myeloid Leukemia (AML)

NCT06641648

Clinical

Trials by Indication[1]

Camrelizumab1 trial

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT05171309·35 enrolled

Acute Myeloid Leukemia (AML)1 trial

A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.

Recruiting·PPeking University First Hospital·Phase 1·NCT06641648·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NK cell. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NK cell compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NK cell. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanfang Hospital, Southern Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: NNanfang Hospital, Southern Medical University

NK cell

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Camrelizumab1 trial

Acute Myeloid Leukemia (AML)1 trial

References

Drug Info

Quick Facts

Related News